Literature DB >> 17571915

Tolerability of an equimolar mix of nitrous oxide and oxygen during painful procedures in very elderly patients.

Carole Bauer1, Hayat Lahjibi-Paulet, Dominique Somme, Peter Onody, Olivier Saint Jean, Mathilde Gisselbrecht.   

Abstract

BACKGROUND AND
OBJECTIVE: Although an equimolar mix of nitrous oxide-oxygen (N(2)O/O(2)) [Kalinox] is widely used as an analgesic, there have been few specific studies of this product in the elderly. In this article, we investigate the tolerability of this equimolar mix in very elderly patients undergoing painful procedures.
METHODS: This was a prospective, observational study of patients hospitalised in the geriatric short-stay unit of a teaching hospital between July 2001 and September 2003. All patients aged >/=80 years who were scheduled for invasive care procedures were eligible for inclusion. Sixty-two patients were recruited and underwent a total of 68 procedures. The procedures were divided into four classes based on the degree of pain they were expected to cause and their duration. Patients received the equimolar N(2)O/O(2) mix (Kalinox) for 5 minutes before the beginning of the procedure and throughout its duration. The inhaled treatment was administered via a high-concentration mask. Assessments were carried out during the inhalation and over the 15 minute period following inhalation. The primary endpoint of the study was tolerability of the equimolar N(2)O/O(2) mix, and all adverse events were recorded. Secondary endpoints were the efficacy of the product (assessed on a verbal rating scale and/or the Doloplus scale), its ease of use and its acceptability to patients and staff.
RESULTS: Fourteen patients (22.6%) each reported at least one adverse event: impaired hearing (n = 1), altered perception of the environment (n = 8), anxiety (n = 1), headache (n = 3) and drowsiness at the end of the procedure (n = 2). All these disorders subsided rapidly after treatment was completed.
CONCLUSION: This study shows the favourable tolerability of the equimolar N(2)O/O(2) mix in very elderly subjects, which makes this product a valuable tool for the management of acute pain in this age group.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17571915     DOI: 10.2165/00002512-200724060-00006

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  25 in total

1.  A prospective multicentric trial for effectiveness and tolerance of a N2O/O2 premix used as a sedative drug.

Authors:  Martine Hennequin; Marie-Cécile Manière; Sylvie Albecker-Grappe; Denise Faulks; Annie Berthet; Corinne Tardieu; Dominique Droz; Maryse Wolikow; Serge Koscielny; Peter Onody
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

2.  The psychometric quality and clinical usefulness of three pain assessment tools for elderly people with dementia.

Authors:  Sandra M G Zwakhalen; Jan P H Hamers; Martijn P F Berger
Journal:  Pain       Date:  2006-08-04       Impact factor: 6.961

Review 3.  Pain management in older adults: prevention and treatment.

Authors:  F M Gloth
Journal:  J Am Geriatr Soc       Date:  2001-02       Impact factor: 5.562

4.  Age-related morphine kinetics.

Authors:  J A Owen; D S Sitar; L Berger; L Brownell; P C Duke; P A Mitenko
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

5.  Patient-administered nitrous oxide/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: a randomized placebo-controlled trial.

Authors:  L Castéra; I Nègre; K Samii; C Buffet
Journal:  Am J Gastroenterol       Date:  2001-05       Impact factor: 10.864

6.  Effectiveness of 50% nitrous oxide/50% oxygen during laceration repair in children.

Authors:  J H Burton; T E Auble; S M Fuchs
Journal:  Acad Emerg Med       Date:  1998-02       Impact factor: 3.451

7.  Nitrous oxide for colonoscopy: a randomized controlled study.

Authors:  G M Forbes; B J Collins
Journal:  Gastrointest Endosc       Date:  2000-03       Impact factor: 9.427

8.  [Use of MEOPA (nitrogen monoxide-oxygen mixture) as analgesic for prostate biopsies].

Authors:  Jean-Alexandre Long; Arnaud Manel; Ronan Moalic; Jean-Michel Pellat; Bernard Boillot; Jean-Luc Descotes; Jean-Jacques Rambeaud
Journal:  Prog Urol       Date:  2004-12       Impact factor: 0.915

9.  Prefixed equimolar nitrous oxide and oxygen mixture reduces discomfort during flexible bronchoscopy in adult patients: a randomized, controlled, double-blind trial.

Authors:  Kinan Atassi; Gilles Mangiapan; Claire Fuhrman; Stéphane Lasry; Peter Onody; Bruno Housset
Journal:  Chest       Date:  2005-08       Impact factor: 9.410

10.  Entonox: too useful to be limited to childbirth?

Authors:  K Lawler
Journal:  Prof Care Mother Child       Date:  1995
View more
  5 in total

Review 1.  Breakthrough pain in elderly patients with cancer: treatment options.

Authors:  Sophie Pautex; Nicole Vogt-Ferrier; Gilbert B Zulian
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

2.  Analgesic efficacy of equimolar 50% nitrous oxide/oxygen gas premix (Kalinox®) as compared with a 5% eutectic mixture of lidocaine/prilocaine (EMLA®) in chronic leg ulcer debridement.

Authors:  Juerg Traber; Ulrike Held; Maria Signer; Tobias Huebner; Stefan Arndt; Thomas A Neff
Journal:  Int Wound J       Date:  2016-08-08       Impact factor: 3.315

3.  Inhaled nitrous oxide can reduce the pain perception in post Caldwell-Luc operation patients-a randomised trial.

Authors:  Ting Dong; Mingwen Liu; Kun Lv
Journal:  Sci Rep       Date:  2017-12-19       Impact factor: 4.379

Review 4.  Measurement properties, feasibility and clinical utility of the Doloplus-2 pain scale in older adults with cognitive impairment: a systematic review.

Authors:  Hanne Marie Rostad; Inger Utne; Ellen Karine Grov; Martine Puts; Liv Halvorsrud
Journal:  BMC Geriatr       Date:  2017-11-02       Impact factor: 3.921

5.  Interest of 50% nitrous oxide and oxygen premix sedation in gerodontology.

Authors:  Emmanuel Nicolas; Claire Lassauzay
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.